Our science
ReCerise Therapeutics identifies upstream immune regulators that operate across seemingly distinct disease areas
such as cancer, inflammation, fibrosis, and metabolic disorders.
Based on these targets, we are developing the following:
1. Targeted antibody therapeutics
We develop first-in-class targeted therapies by leveraging multiple antibody formats,
including monoclonal, multi-specifics, and ADCs, to suppress pathological signals that drive tissue injury
while selectively eliminating tumor tissues that depend on pathological microenvironments.
2. Biomarkers and companion diagnostics
We use target expression, immune-metabolic signatures, and circulating biomarkers
to identify which patients are most likely to benefit from our therapeutics.
We are building an integrated companion diagnostics and patient-selection platform
that can be expanded into IHC, molecular diagnostics, and blood-based assays.
3. Microenvironment-level modulation
We move beyond a single organ or indication and aim to redesign, at an upstream level, the immune-metabolic networks
with the goal of protecting tissues from damage while reversing pathological microenvironments and tumor burden.
Through this integrated “target–therapy–diagnostic” strategy, ReCerise investigates targets that are preferentially expressed and
functionally engaged in the gastrointestinal tract, and aims to deliver precise antibody therapies and companion diagnostic solutions
for cancer and a broad range of difficult-to-treat diseases.
Progress
